Amylyx Pharmaceuticals, Inc. AMLX Return on invested capital
Return on invested capital at other companies
Other financials
Where this comes from
Calculated from Amylyx Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s return on invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s return on invested capital?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported return on invested capital of -165.3% in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s return on invested capital changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s return on invested capital decreased by 7.8% year-over-year, from -153.3% to -165.3%.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s return on invested capital?
- Over 2 years (2023 to 2025), Amylyx Pharmaceuticals, Inc.'s return on invested capital has grown at a 271.7% compound annual growth rate (CAGR), from 12.8% to -176.3%.
- What does return on invested capital mean?
- Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.